Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 8Endocrine 4Thoracic 1Other solid neoplasm 1Other 1NET 1Head & Neck 1Gastrointestinal 1

Conditions

Neuroendocrine Tumors 148Gastro-enteropancreatic neuroendocrine tumor 29Carcinoma, Neuroendocrine 18Neoplasms 16Breast Neoplasms 13Adenoma, Islet Cell 13Prostatic Neoplasms 11Carcinoma, Hepatocellular 11Carcinoid Tumor 11Stomach Neoplasms 10Pheochromocytoma 10Pancreatic Neoplasms 10Colorectal Neoplasms 10Sarcoma 9Paraganglioma 9Thyroid Neoplasms 8Neoplasm Metastasis 8Lung Neoplasms 8Cholangiocarcinoma 8Small Cell Lung Carcinoma 7Ovarian Neoplasms 7Melanoma 7Esophageal Neoplasms 7Anus Neoplasms 7Rectal Neoplasms 6Mesothelioma 6Colonic Neoplasms 6Carcinoma 6Brain Neoplasms 6Uterine Cervical Neoplasms 5

Interventions

fluorodopa F 18 1Furosemide 14-chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Parkinson Disease × NET × 1 year × Clear all
NCT04706910 2026-02-09

18F-DOPA II - PET Imaging Optimization

University of Alberta

Phase 3 Recruiting
800 enrolled
CNSEndocrineNET

Brain Neoplasms, Neuroblastoma, Parkinson Disease, Neuroendocrine Tumors, Lewy Body Disease, Congenital Hyperinsulinism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡